Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
by
Arun K. Nalla 1 and Grant D. Trobridge 1,2,*
Arun K. Nalla 1 and Grant D. Trobridge 1,2,*
1
Pharmaceutical Sciences, College of Pharmacy, Washington State University Spokane, Spokane, WA 99202, USA
2
School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Kenneth Cornetta
Biomedicines 2016, 4(2), 8; https://doi.org/10.3390/biomedicines4020008
Received: 29 January 2016 / Revised: 18 March 2016 / Accepted: 23 March 2016 / Published: 29 March 2016
(This article belongs to the Special Issue Gene Therapy Strategies for HIV/AIDS)
Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV.
View Full-Text
Keywords:
gene therapy; retroviral vector; foamy viruses; anti-HIV transgenes
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Nalla, A.K.; Trobridge, G.D. Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. Biomedicines 2016, 4, 8.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
